Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
